On the minus side, downtrend line going back to August held yesterday but broke below today. I really didn't like the way some draw it anyway and think a line from August to the stop around $0.36 is a better reflection of a resistance. Not to mention over bought on the RSI ect.
On the positive side, bounced and held above the 200 DMA.
May still need work on the gap area in the $0.28's but the right news could show a quick recovery.
We need serious volume to break out again.
You are simply cannot be honest with yourself.
***Still curious to see what will happen if it breaks 0.38 to see if Bill O'Neil is right on those cup formations. Looking back on the six month chart, it's almost formed a perfect cup***
As I said, not completely impossible. I do not believe the same set-up is there. Different players, but a small chance.
As far as data....preclinical burn data and a small number of cardiac patients from a halted and difficult to enroll unlikely justifies a tripling of the PPS. If you want to consider the cup and handle breakout the Bill O'Neil says that usually results in a 30% move...also far short of $1.00.
$1.00 is a tall order.
All hope lies in burn and heart data in early May.
While not impossible, I think it is next to impossible. The data coming isn't the type to justify such a move imho.
As far as Rodney suggesting a 1:5 R/S....that would be a total bonehead move by management.
*** I hope to here the FDA approving this new "drug", ECCS-50, for immediate use by this summer!***
***Hmmm, I don't think I mentioned anything about the chances of a RS in my post. Please don't put words in my mouth***
You should check your post.
***I disagree with the medical community not embracing autologous cells. There are quite a few self-funded trials going on worldwide at this time***
There have been plenty of these small trials over the years...10 yrs later still waiting. CC was too cheap to run trials and the ones he did run ended with nothing to show but screw-ups.
***Cytori's sales will increase exponentially and off-label use for other indications will be enormous.***
Not in the USA...this is EXACTLY what the FDA is trying to avoid.
***I guess all of the great results that Okyanos is achieving with the technology are just a farce also?***
Almost meaningless in the handful of sales...you need trials then reimbursement for big $$$.
***Time will tell.***
Hopefully the future is better, lets just keep the history correct.
Foo also ignores Cytori has gone the medical community/Doctor route for years and still hasn't produced a approved product. Foo happy we are following FDA but ignores the wasted time and money suing the FDA.
Foo's view on autologous vs allogeneic is yet to be proven who wins.
Foo also says no chance of a reverse split...we will get that answer soon enough.
Potential pluses and minuses but all we know for sure is Maxim gets paid again.
rothco....maybe they want to make you happy after all...LOL !
Still not enough volume imho to move a stock with 195 million shares out other than small moves up or down
Trial news can cut both ways as we saw with the early OA peek
typical YMB...only half of reply posted.
Anyway....this news resulted in a 38% DECLINE in PPS for VCEL....but there was a big run ahead of time so looks like a sell the news event unless they expected something more.
Of note was the 109 patients they were able to enroll. Cytori struggled to get just a handful before trial stoppage. Cytori to present data on these few patients in about a month.
The double-blind trial found that the group treated with cell therapy had fewer deaths compared to the placebo group (8 vs. 4) and fewer heart failure related hospitalizations (42 of 51 vs. 30 of 58, or 82.4 percent vs. 51.7 percent with a p-value of 0.01), contributing to a 37 percent overall reduction in cardiac events. Any effects beyond one year remain unknown. The study also reported that there were no, or only very small, statistically significant differences in measures of heart function including performance in an exercise tolerance test, left ventricular ejection fraction, left ventricular end diastolic volume, and left ventricular end systolic volume. A larger sample size may discern other differences between patients who receive treatment and those who do not.
*** The stock flatlines for the next 24 months***
That is actually a huge positive over the last 10 years...LOL
Just to clarify...for that type of app.
4k...likely a average with cardiac costing the most with a 10K average.